PCSK9 and familial hypercholesterolemia: Moreover, the identification of two seemingly healthy individuals carrying LOF mutations in both alleles, which lead to a complete absence of circulating PCSK9 and correlating with very low plasma LDL-cholesterol levels was a major breakthrough that encouraged the scientific community to develop PCSK9 inhibitors as a novel treatment of hypercholesterolemia [1].